INTRODUCTION
In Germany, with the introduction of the new Arzneimittelmarktneuordnungsgesetz (AMNOG) in 2011, the pricing regulations for newly authorized pharmaceuticals and their reimbursement by statutory health insurance providers has changed. Now, there are three main stakeholders: the Joint Federal Committee (G-BA 1 ), the Institute for Quality and Efficiency in Health Care (IQWiG 2 ) and the National Association of Statutory Health Insurance Funds (GKV-SV 3 ). G-BA is a committee of the joint self-government of physicians, hospitals and health insurance funds. It evaluates the benefits of pharmaceuticals using a standardized procedure that follows the criteria of evidence-based medicine. IQWiG helps G-BA to fulfil its legal responsibilities by issuing scientific recommendations.* 1 The list price of a product is set by the manufacturer upon launch. After negotiations with the GKV-SV, a commonly undisclosed price rebate or reference price for the statutory health insurance providers is agreed on the grounds of the AMNOG assessment.* 2 The manufacturer has the option to unilaterally end the price rebate negotiation procedure within four weeks of the publication of the G-BA resolution, a so-called "opt-out", thereby choosing not to launch the product in Germany. As previous publications 4 have not systematically addressed predictors on the G-BA assessment and its impact on rebate, the aim of this poster is to generate hypotheses on the following topics: 1. Identification of possible predictors for GB-A decisions 2. Determination of the association between added benefit and rebate
CONCLUSIONS & DISCUSSION
• Key factors for a positive G-BA benefit assessment are improved OS, morbidity, and adverse events, demonstrated through the use of direct ZVT comparators.
• ATC-codes J and L carry the highest chance of gaining a positive assessment, and ATC-A code the lowest chance.
• The assessment of the added benefit is not associated with the drug's price level.
• The rebate negotiated with the GKV decreases significantly by 13.1% if any added benefit is determined in at least one subgroup.
• Lack of data volume does not yet allow for inferences on predictive factors for the extent of added benefit.
• The positive impact of quality of life, morbidity, and adverse events might be related to the added benefit of OS. While univariate analysis has shown that they are significant predictors, multivariate analyses need to be conducted to study more complex associations within the data and test hypothesis.
As an added benefit is automatically assumed for orphan drugs, the G-BA does not require a relevant scientific assessment by IQWiG. Submissions do not need to provide documents on comparators. * In total, 60.3% of all G-BA drug assessments resulted in an added benefit.* 2
• Among 40 subgroups with ATC-code L (27 drugs), G-BA concluded an added benefit for 70% (86%), with 50% of them demonstrating added benefit in OS. Out of 38 subgroups with ATC-code A (13 drugs), 13% (31%) resulted in added benefit, with 0% demonstrating added benefit in OS.
• In 12 out of 13 benefit assessments where IQWiG and G-BA disagreed if added benefit was proven, G-BA granted a higher added benefit for the new drug than IQWiG. Even if assessment outcomes were equivalent between IQWiG and G-BA, decisions were sometimes substantiated differently.
• Manufacturers presented surrogate endpoints in 21 submissions (excluding orphan drugs* 1 ), which were accepted by IQWiG in three cases.
• Relative risk calculation (p<0.05) showed that the likelihood to achieve added benefit was: 1) 70% less likely for ATC-code A, and more than twice as likely for ATC-codes J and L (RR=0.3; 2.3; 2.5)* 5 2) Two to three times as likely if the G-BA accepted evidence on improvements in OS, quality of life, morbidity, or adverse events (RR=3.1; 2.2; 3.5; 2.9) 3) Eight to ten times as likely if direct comparators or the ZVT were used (RR=9.6; 7.6)* 6 • Odds ratios are reported in Table 1. • Univariate logistic regression showed a significant relationship between these characteristics and added benefit (see Table 1 ). All drugs showing an advantage in Overall Survival (OS) resulted in added benefit. Study design, price level of the drug, and surrogate endpoints used were no predictors of added benefit. • The average rebate for drugs without added benefit was 32.3%, for drugs with added benefit 19.2%.
T-Test showed a significant association between added benefit and rebate (p<0.05; CI: 5.3% -25.6%).
RESULTS

METHODS
All G-BA decisions up to March 2014 were included in the analysis. The dossier submitted by the manufacturer as well as the IQWiQ assessment, G-BA decisions and price rebates were reviewed. Information was obtained directly from the G-BA website. 2 Where needed, external sources were consulted. 5, 6 Under AMNOG, the benefit is assessed for every subpopulation identified by IQWiG and G-BA for each product, and the outcome may be different between these subgroups. Hence, assessment outcomes were analyzed by subgroup and not by product, unless otherwise specified. Relative risk calculations as well as univariate logistic regression were used to investigate the relationship of G-BA decisions with product and study characteristics assumed as relevant.* 3 Dependent variable: Added benefit (y/n) per subgroup, where any benefit ranging from not quantifiable to major was considered added benefit. Independent variables:
• Disease area (ATC-code) • Study design of submitted trials (superiority/non-inferiority), comparators used (in/direct; adequate comparator [ZVT] according to GBA y/n), surrogate endpoints used (y/n) • Main area of claimed benefit e.g. overall survival (OS), price level (low -very high) Linear regression was used to assess the impact of a drug's added benefit* 4 on rebate. Linear regression was used to assess the impact of added benefit in at least one subgroup of a drug on the extent of the rebate. 
